Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s

Published 02 Oct 2026, 15:26 UTC. Updated 04 Oct 2026, 12:08 UTC.

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Directly affected

LLY Eli Lilly
Named in this report.

Indirectly affected

AIPO DEFIANCE AI & POWER INFRASTRUCTURE ETF
GA selected AIPO as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
EAPR INNOVATOR EMERGING MARKETS POWER BUFFER ETF - APRIL
GA selected EAPR as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
EJAN INNOVATOR EMERGING MARKETS POWER BUFFER ETF JANUARY
GA selected EJAN as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
EJUL INNOVATOR EMERGING MARKETS POWER BUFFER ETF - JULY
GA selected EJUL as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
GASZ CORGI ETF TR I NAT GAS POWER &
GA selected GASZ as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
IAUG INNOVATOR INTERNATIONAL DEVELOPED POWER BUFFER ETF AUGUST
GA selected IAUG as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.

Price reaction, T-5 to T+3

Ticker	T-5	T-3	T-1	T0	T+1	T+2	T+3
LLY	—	—	—	—	—	—	—
AIPO	—	—	—	—	—	—	—
EAPR	—	—	—	—	—	—	—
EJAN	—	—	—	—	—	—	—
EJUL	—	—	—	—	—	—	—
GASZ	—	—	—	—	—	—	—
IAUG	—	—	—	—	—	—	—

Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes.

Source: CNBC Top

The price since 2 Oct 2026: Eli Lilly (LLY) versus the S&P 500

Since the first closing price after “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s,” Eli Lilly (LLY) is +8.41%. The S&P 500 fund (SPY) is -1.08% over the same days, a +9.49% difference versus the market.

LLY

SPY

Filings that name Eli Lilly (LLY) around 2 Oct 2026

Rohit Khanna buy Eli Lilly (LLY) ($1,001 - $15,000). That is 28 days before publication, inside 30 days. The filing is listed beside the story “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s.”

Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).

Who gains and who loses around Eli Lilly (LLY)

Companies carried with this story

LLY Eli Lilly
For “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s,” Eli Lilly (LLY) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names ELI LILLY & CO in the summary; GA resolved that company to LLY
AIPO Defiance Ai & Power Infrastructure Etf
Defiance Ai & Power Infrastructure Etf (AIPO) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s.” Reason on file: GA selected AIPO as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
EAPR Innovator Emerging Markets Power Buffer Etf - April
In “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s,” Innovator Emerging Markets Power Buffer Etf - April (EAPR) is linked, with no stored direction, medium confidence. Reason on file: GA selected EAPR as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
EJAN Innovator Emerging Markets Power Buffer Etf January
For “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s,” Innovator Emerging Markets Power Buffer Etf January (EJAN) is linked, with no stored direction, medium confidence. Reason on file: GA selected EJAN as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
EJUL Innovator Emerging Markets Power Buffer Etf - July
Innovator Emerging Markets Power Buffer Etf - July (EJUL) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s.” Reason on file: GA selected EJUL as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
GASZ Corgi Etf Tr I Nat Gas Power
In “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s,” Corgi Etf Tr I Nat Gas Power (GASZ) is linked, with no stored direction, medium confidence. Reason on file: GA selected GASZ as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
IAUG Innovator International Developed Power Buffer Etf August
Innovator International Developed Power Buffer Etf August (IAUG) is linked, with no stored direction, medium confidence in the 2 Oct 2026 story “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s.” Reason on file: GA selected IAUG as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

Eli Lilly (LLY)

On 2 Oct 2026, “Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s” is the story that connects Eli Lilly (LLY) to this story.

The link for Eli Lilly (LLY) is this: The reported development directly names ELI LILLY & CO in the summary; GA resolved that company to LLY

Also listed, Defiance Ai & Power Infrastructure Etf (AIPO): GA selected AIPO as a RELATED security because its canonical security name directly matches this event's themes: power. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article

Dates in the story, and the Eli Lilly (LLY) price range

AIPO traded between 25.36 and 30.23 across 20 sessions. The latest close on file is 25.71. EAPR traded between 32.93 and 34.30 across 9 sessions. The latest close on file is 32.96. LLY traded between 1131.55 and 1275.56 across 20 sessions. The latest close on file is 1240.65.

How strong the case is around Eli Lilly (LLY)

46 out of 100

“Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.